Stephan Eisenmann1,2, Wolfgang Schütte3, Faustina Funke4, Filiz Oezkan4, Shaheen Islam5, Kaid Darwiche4. 1. Interventional Pneumology, Ruhrlandklinik-West German Lung Center, Essen, Germany. stephan.eisenmann@uk-halle.de. 2. Department of Pulmonary Medicine, University of Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle, Germany. stephan.eisenmann@uk-halle.de. 3. Martha-Maria Hospital Halle-Dölau, Halle, Germany. 4. Interventional Pneumology, Ruhrlandklinik-West German Lung Center, Essen, Germany. 5. Interventional Pulmonology, Ohio State University, Columbus, USA.
Abstract
PURPOSE: Bronchial Thermoplasty (BT) is indicated in patients suffering from severe and symptomatic bronchial asthma despite maximal medical therapy. However, treatment of the right middle lobe (RML) bronchus is currently not recommended. The aim of this study was to investigate the safety and efficacy of BT if the RML bronchus is included. METHODS: BT was performed in 17 consecutive patients, quality of life and pulmonary function were characterized before and 90 days after BT completion. Furthermore, we performed a clean-up bronchoscopy following every BT. This study was approved by the IRB of the University of Essen (No. 17-7356 BO) and registered as a retrospective observational study at the German Clinical Trials Registry (No. DRKS 00011550). RESULTS: The median baseline values of FEV1 and Asthma Questionnaire of Life Quality (AQLQ) were 1.33 l (0.91; 1.73) and 3.01 (2.76; 3.61), respectively, and significantly improved 90 days after treatment with FEV 1 at 1.75 l (p-value 0.002) and AQLQ 3.8 (p-value < 0.05). Also the amount of oral corticosteroid necessity decreased significantly. No severe adverse events occurred due to the procedure. Clean-up bronchoscopies-when performed-revealed significant fibrinous exudation after every BT procedure. CONCLUSION: BT including the RML bronchus is feasible. Functionally limited patients with severe asthma could potentially profit. Due to the relevant fibrinous exudation, BT should be followed by clean-up bronchoscopy, not only after RML treatment.
PURPOSE: Bronchial Thermoplasty (BT) is indicated in patients suffering from severe and symptomatic bronchial asthma despite maximal medical therapy. However, treatment of the right middle lobe (RML) bronchus is currently not recommended. The aim of this study was to investigate the safety and efficacy of BT if the RML bronchus is included. METHODS: BT was performed in 17 consecutive patients, quality of life and pulmonary function were characterized before and 90 days after BT completion. Furthermore, we performed a clean-up bronchoscopy following every BT. This study was approved by the IRB of the University of Essen (No. 17-7356 BO) and registered as a retrospective observational study at the German Clinical Trials Registry (No. DRKS 00011550). RESULTS: The median baseline values of FEV1 and Asthma Questionnaire of Life Quality (AQLQ) were 1.33 l (0.91; 1.73) and 3.01 (2.76; 3.61), respectively, and significantly improved 90 days after treatment with FEV 1 at 1.75 l (p-value 0.002) and AQLQ 3.8 (p-value < 0.05). Also the amount of oral corticosteroid necessity decreased significantly. No severe adverse events occurred due to the procedure. Clean-up bronchoscopies-when performed-revealed significant fibrinous exudation after every BT procedure. CONCLUSION: BT including the RML bronchus is feasible. Functionally limited patients with severe asthma could potentially profit. Due to the relevant fibrinous exudation, BT should be followed by clean-up bronchoscopy, not only after RML treatment.
Authors: Enid M Eslick; Dale L Bailey; Benjamin Harris; John Kipritidis; Mark Stevens; Bob T Li; Elizabeth Bailey; Denis Gradinscak; Sean Pollock; Chris Htun; Robin Turner; Thomas Eade; Ali Aslani; Graeme Snowdon; Paul J Keall Journal: Eur J Cardiothorac Surg Date: 2015-08-06 Impact factor: 4.191
Authors: Michael E Wechsler; Michel Laviolette; Adalberto S Rubin; Jussara Fiterman; Jose R Lapa e Silva; Pallav L Shah; Elie Fiss; Ronald Olivenstein; Neil C Thomson; Robert M Niven; Ian D Pavord; Michael Simoff; Jeff B Hales; Charlene McEvoy; Dirk-Jan Slebos; Mark Holmes; Martin J Phillips; Serpil C Erzurum; Nicola A Hanania; Kaharu Sumino; Monica Kraft; Gerard Cox; Daniel H Sterman; Kyle Hogarth; Joel N Kline; Adel H Mansur; Brian E Louie; William M Leeds; Richard G Barbers; John H M Austin; Narinder S Shargill; John Quiring; Brian Armstrong; Mario Castro Journal: J Allergy Clin Immunol Date: 2013-08-30 Impact factor: 10.793
Authors: Geoffrey Chupp; Michel Laviolette; Lauren Cohn; Charlene McEvoy; Sandeep Bansal; Adrian Shifren; Sumita Khatri; G Mark Grubb; Edmund McMullen; Racho Strauven; Joel N Kline Journal: Eur Respir J Date: 2017-08-31 Impact factor: 16.671